SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2016 / Cilt: 44 - Sayı: 6

Kalp yetersizliği bulunan ejeksiyon fraksiyonu düşük hastalarda B1 adrenerjik reseptör ve sitokrom p450 2D6 enzimi genetik polimorfizmi sıklığı ve beta bloker tolerabilitesi üzerine etkisi: Beta GenTURK çalışması

Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study

Hakkı KAYA
Yüksel ÇAVUŞOĞLU
Şerafettin DEMİR
Ceyhun YÜCEL
Mehdi ZOGHİ
Haşim MUTLU
Oktay ERGENE
Enbiya AKSAKAL
Mehmet Birhan YILMAZ
Pages
457–465
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The HFREF patients were separated into 2 subgroups based on achievement of maximal target dose (MTD) of BB.Results: When comparing frequency of genotype distribution for Arg389Gly polymorphism in HFREF patients to the healthy controls, a statistically significant association was observed with CC genotype and Glisin-Glisin (GG) genotype (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy.Methods: A total of 206 HFREF patients and 90 healthy controls were prospectively enrolled.
📊
Key Findings & Data:Genotypes for Arg389Gly and Cyp2D6*10 polymorphisms of the healthy controls and 162 of the 206 heart failure (HF) patients were measured, identified by polymerase-chain-reaction- and restriction-fragment-lengthpolymorphism analysis.
💡
Conclusion & Impact:The HFREF patients were separated into 2 subgroups based on achievement of maximal target dose (MTD) of BB.Results: When comparing frequency of genotype distribution for Arg389Gly polymorphism in HFREF patients to the healthy controls, a statistically significant association was observed with CC genotype and Glisin-Glisin (GG) genotype (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy.Methods: A total of 206 HFREF patients and 90 healthy controls were prospectively enrolled. Genotypes for Arg389Gly and Cyp2D6*10 polymorphisms of the healthy controls and 162 of the 206 heart failure (HF) patients were measured, identified by polymerase-chain-reaction- and restriction-fragment-lengthpolymorphism analysis. HFREF patients and healthy controls were compared regarding Arg389Gly polymorphism. The HFREF patients were separated into 2 subgroups based on achievement of maximal target dose (MTD) of BB.Results: When comparing frequency of genotype distribution for Arg389Gly polymorphism in HFREF patients to the healthy controls, a statistically significant association was observed with CC genotype and Glisin-Glisin (GG) genotype (p

Özet

Bu çalışmanın amacı, ejeksiyon fraksiyonu düşük olup kalp yetersizliği (KY) bulunan hastalarda Arginine389Glycine (Arg389Gly) ve sitokrom p450 2D6*10 (Cyp2D6*10) polimorfizmi sıklıklarını belirlemek ve bu polimorfizmlerin beta bloker (BB) tedavisi yanıtına etkisini değerlendirmektir.Yöntemler: Ejeksiyon fraksiyonu düşük olup KY bulunan 206 hasta ve sağlıklı 90 kişilik kontrol grubu ileriye dönük olarak çalışmaya dahil edildi. Kontrol grubunun tümünün, KY'li 206 hastanın ise 162'sinin Arg389Gly ve Cyp2D6*10 polimorfizmi için genotipleri, polimeraz zincir reaksiyon ve restriksiyon fragman uzunluk polimorfizmi analizi aracılığı ile belirlendi. Azalmış ejeksiyon fraksiyonlu KY'li hastalar ve sağlıklı kontroller Arg389Gly gen polimorfizmi açısından karşılaştırıldı. Ayrıca KY'li hastalar en yüksek BB hedef dozuna ulaşıp ulaşamamalarına göre iki gruba ayrıldı.Bulgular: Azalmış ejeksiyon fraksiyonlu KY'li hastalar ile sağlıklı kontroller arasında Arg389Gly polimorfizmi için genotip dağılım sıklıkları açısından yapılan karşılaştırmada CC ve GG genotipleri ile anlamlı ilişki gözlendi (p

🔖

Cite This Article

KAYA, H., ÇAVUŞOĞLU, Y., DEMİR, Ş., YÜCEL, C., ZOGHİ, M., MUTLU, H., ERGENE, O., AKSAKAL, E., YILMAZ, M. B. (2022). Kalp yetersizliği bulunan ejeksiyon fraksiyonu düşük hastalarda B1 adrenerjik reseptör ve sitokrom p450 2D6 enzimi genetik polimorfizmi sıklığı ve beta bloker tolerabilitesi üzerine etkisi: Beta GenTURK çalışması. Türk Kardiyoloji Derneği Arşivi, Cilt: 44 - Sayı: 6, 457–465. https://ajindex.com/articles/632667

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-90. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988;77:721-30.
  2. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-49. Bristow MR. Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of re- ceptor pharmacology and clinical cardiology. Circ Res 2011;109:1176-94.
  3. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a con- served beta(1)-adrenergic receptor motif alters cardiac func- tion and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006;103:11288-93.
  4. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Scho- field RS, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled re- lease/extended release in heart failure. Clin Pharmacol Ther 2005;77:127-37. de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fad- den E, Foucher-Hossein C, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005;15:137-42.
  5. Taylor MR, Bristow MR. The emerging pharmacogenom- ics of the beta-adrenergic receptors. Congest Heart Fail 2004;10:281-8.
  6. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-ad- renergic receptor signaling is protective in heart failure. Nat Med 2008;14:510-7.
  7. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-func- tion polymorphism in a G-protein coupling domain of the hu- man beta1-adrenergic receptor. J Biol Chem 1999;274:12670- 4. the possibility to address genetic polymorphisms in Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, et al. Role of beta1- and alpha2c-adrenergic receptor polymor- phisms and their combination in heart failure: a case-control study. Eur J Heart Fail 2006;8:131-5.
  8. Fragoso JM, Rodríguez-Pérez JM, González J, Cruz D, Pérez- Méndez O, de Jesus García J, et al. Beta1-adrenergic recep- tor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol 2006;80:279-82.
  9. Canham RM, Das SR, Leonard D, Abdullah SM, Mehta SK, Chung AK, et al. Alpha2cDel322-325 and beta1Arg389 ad- renergic polymorphisms are not associated with